• LAST PRICE
    37.4600
  • TODAY'S CHANGE (%)
    Trending Down-0.2300 (-0.6102%)
  • Bid / Lots
    37.4400/ 1
  • Ask / Lots
    37.5600/ 4
  • Open / Previous Close
    37.6000 / 37.6900
  • Day Range
    Low 37.0000
    High 37.6400
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    36,837
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 37.69
TimeVolumeXENE
09:32 ET54637.6
09:43 ET40037.35
09:48 ET10037.355
09:50 ET10037.13
09:54 ET79837.33
09:56 ET90037.47
09:57 ET10037.585
10:01 ET10037.47
10:03 ET10037.61
10:06 ET41937.6
10:12 ET65237.37
10:19 ET664837.375
10:21 ET20037.315
10:24 ET338337.13
10:30 ET10037.21
10:32 ET20037.185
10:35 ET12837.2
10:42 ET10037.21
10:44 ET10037.16
10:51 ET20037.23
10:53 ET10037.16
10:55 ET130137.1
10:57 ET78437
11:09 ET98437.205
11:20 ET50037.4
11:22 ET118137.5
11:26 ET40037.48
11:31 ET502737.48
11:36 ET10037.46
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
2.8B
-13.8x
---
United StatesSWTX
SpringWorks Therapeutics Inc
2.9B
-7.3x
---
United StatesMLTX
MoonLake Immunotherapeutics
2.7B
-55.3x
---
United StatesGERN
Geron Corp
2.6B
-12.2x
---
United StatesBHVN
Biohaven Ltd
3.1B
-5.1x
---
United StatesIDYA
IDEAYA Biosciences Inc
2.7B
-17.3x
---
As of 2024-07-02

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

Chairman of the Board
Simon Pimstone
President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.8B
Revenue (TTM)
$0.00
Shares Outstanding
75.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.27
EPS
$-2.71
Book Value
$12.31
P/E Ratio
-13.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.